Last reviewed · How we verify
Rituximab and DexaBEAM
Rituximab and DexaBEAM is a Small molecule drug developed by Georg Hess, MD. It is currently in Phase 2 development. Also known as: Rituxan.
At a glance
| Generic name | Rituximab and DexaBEAM |
|---|---|
| Also known as | Rituxan |
| Sponsor | Georg Hess, MD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rituximab and DexaBEAM CI brief — competitive landscape report
- Rituximab and DexaBEAM updates RSS · CI watch RSS
- Georg Hess, MD portfolio CI
Frequently asked questions about Rituximab and DexaBEAM
What is Rituximab and DexaBEAM?
Rituximab and DexaBEAM is a Small molecule drug developed by Georg Hess, MD.
Who makes Rituximab and DexaBEAM?
Rituximab and DexaBEAM is developed by Georg Hess, MD (see full Georg Hess, MD pipeline at /company/georg-hess-md).
Is Rituximab and DexaBEAM also known as anything else?
Rituximab and DexaBEAM is also known as Rituxan.
What development phase is Rituximab and DexaBEAM in?
Rituximab and DexaBEAM is in Phase 2.
Related
- Manufacturer: Georg Hess, MD — full pipeline
- Also known as: Rituxan
- Compare: Rituximab and DexaBEAM vs similar drugs
- Pricing: Rituximab and DexaBEAM cost, discount & access